ARYx gets FDA nod on tecarfarin path

In an attempt to right course on the experimental blood thinner tecarfarin, ARYx Therape tics said this morning that the FDA had confirmed it is on the right development path for a regulatory approval. The oral drug failed a Phase II/III trial last summer, triggering a sharp drop in the company's stock price. The FDA said that an additional trial that compares the experimental therapy with warfarin in a real-world setting could be used to obtain an approval. "We anticipate continuing this dialogue with the FDA as we now seek their approval for the specific design of the real-world trial through a Special Protocol Assessment," Chief Executive Paul Goddard said in a statement. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.